1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Wang, M.; Arnason, J. E.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • High quality neoantigens are immunoedited in long-term pancreatic cancer survivors
    Meeting Abstract

    Sethna, Z.; Luksza, M.; Rojas, L.; Soares, K.; Leung, J.; Lihm, J.; Hoyos, D.; Dobrin, A.; Kappagantula, R.; Makohon-Moore, A.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; George, M.; Venkatesh, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
    Meeting Abstract

    Sacco, J.; Carvajal, R.; Butler, M.; Shoushtari, A.; Hassel, J.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients
    Meeting Abstract

    Knorr, D.; Ravetch, J.; D'Andrea, G.; Vahdat, L.; Klebanoff, C.; Robson, M.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Schoenfeld, A.; Lee, S.; Paz-Ares, L.; Doger, B.; Gettinger, S.; Haefliger, S.; Orcurto, A.; Sukari, A.; Papa, S.; Moreno, J. F. R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
    Meeting Abstract

    Kuryk, L.; Moller, A. S.; Kumar, S.; Shoushtari, A.; Ares, L. P.; Jaderberg, M.; Wiklund, E. D.; Levitsky, V.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma
    Meeting Abstract

    McKean, M.; Luke, J.; Lakhani, N.; Bashir, B.; Aggen, D.; Tan, A.; Kacena, K.; Wang, L.; Timothy, M.; Santillana, S.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T Cells (letetresgene autoleucel)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Eleftheriadou, I.; Huff, A.; Nathenson, M.; Druta, M.; Van Tine, B.; Somaiah, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save